FCP
MRK icon

Fidelis Capital Partners’s Merck MRK Stock Holding History

Fidelis Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64M Buy
51,693
+4,022
+8% +$471K 0.38% 57
2026
Q1 		$5.73M Sell
47,671
-1,447
-3% -$167K 0.41% 51
2025
Q4 		$5.17M Buy
49,118
+9,029
+23% +$848K 0.38% 57
2025
Q3 		$3.36M Buy
40,089
+3,804
+10% +$313K 0.26% 76
2025
Q2 		$2.88M Sell
36,285
-798
-2% -$63.4K 0.26% 73
2025
Q1 		$3.07M Sell
37,083
-9,488
-20% -$886K 0.33% 65
2024
Q4 		$4.65M Buy
46,571
+4,297
+10% +$443K 0.46% 46
2024
Q3 		$4.5M Buy
42,274
+1,298
+3% +$154K 0.54% 38
2024
Q2 		$4.61M Buy
40,976
+2,949
+8% +$380K 0.66% 30
2024
Q1 		$5.02M Buy
38,027
+4,640
+14% +$572K 0.76% 28
2023
Q4 		$3.64M Buy
33,387
+12,534
+60% +$1.3M 0.81% 24
2023
Q3 		$2.15M Buy
20,853
+1,186
+6% +$128K 0.73% 26
2023
Q2 		$2.27M Buy
19,667
+1,325
+7% +$150K 0.83% 24
2023
Q1 		$2.16M Buy
18,342
+7,792
+74% +$841K 0.92% 19
2022
Q4 		$1.16M Buy
+10,550
New +$1.08M 1.37% 17

Other funds holding MRK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelis Capital Partners's MRK Position: Q2 2026 in Review

Fidelis Capital Partners increased its Merck (MRK) stake by 8.4% in Q2 2026, buying an estimated $471K and bringing the position to 51,693 shares worth $6.64M. The position accounts for 0.38% of the portfolio, ranked #57.

Fidelis Capital Partners first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. 3,836 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Fidelis Capital Partners held 51,693 shares of Merck worth $6.64M as of Q2 2026.
  • Fidelis Capital Partners bought 4,022 Merck shares in Q2 2026, an estimated $471K.
  • Merck made up 0.38% of Fidelis Capital Partners's portfolio in Q2 2026, its #57 holding.
  • Fidelis Capital Partners first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • 3,836 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.